Price$1.66+0.04 (+2.47%)
01:30 PM06:30 PM
News · 26 weeks43-100%
2025-12-142026-06-07
Mix3590d
- SEC Filings11(31%)
- Other9(26%)
- Insider9(26%)
- Earnings3(9%)
- Analyst2(6%)
- Offering1(3%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by InflaRx N.V.SCHEDULE 13G - InflaRx N.V. (0001708688) (Subject)
- ANALYSTInflaRx upgraded by Raymond James with a new price targetRaymond James upgraded InflaRx from Outperform to Strong Buy and set a new price target of $9.00
- PRInflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary SharesJena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150 million, before deducting the underwriting discount and offering expenses. The Company intends to use the net proceeds from the offering to advance its pipeline activities and for working capital and general corporate purposes. The financing included participation from new and existi
- SECSEC Form 6-K filed by InflaRx N.V.6-K - InflaRx N.V. (0001708688) (Filer)
- SECSEC Form 424B5 filed by InflaRx N.V.424B5 - InflaRx N.V. (0001708688) (Filer)
- SECSEC Form 424B5 filed by InflaRx N.V.424B5 - InflaRx N.V. (0001708688) (Filer)
- SECSEC Form 6-K filed by InflaRx N.V.6-K - InflaRx N.V. (0001708688) (Filer)
- PRInflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary SharesJena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX) (the "Company"), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to advance its pipeline activities and for working capital and general corporate purposes. The financing inc
- PRInflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal DiseasesInflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseasesCapital Markets Day highlighting the promise and potential of izicopan in AAV and broader renal disorders now planned for summer 2026The Company estimates it will have sufficient funds for currently planned clinical development activities and ongoing operations through 2029InflaRx will continue to engage in dialog with potential collaborators to advance its development goals with izicopan across all geographiesThe Company will host a webcast to discuss its new strategy in AAV and renal disease on Friday, May 8, at 8
- SECSEC Form 6-K filed by InflaRx N.V.6-K - InflaRx N.V. (0001708688) (Filer)
- SECSEC Form 6-K filed by InflaRx N.V.6-K - InflaRx N.V. (0001708688) (Filer)
- PRInflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver MicrosomesJENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new pre-clinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Reactive metabolite formation is widely used in drug development as an early mechanistic indicator of potential bioactivation-related safety risk. Izicopan is an investigational next-generation oral C5aR1 inhibitor designed to achieve differentiated pharmacological properties, with the potential for improved efficacy and safety. The marketed comparator, avacopan, is a first-in-class oral
- PRInflaRx to Report First Quarter 2026 Results on May 7, 2026JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the first quarter 2026 on May 7, 2026, before the market opens. No conference call is planned. About InflaRxInflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inf
- SECSEC Form 6-K filed by InflaRx N.V.6-K - InflaRx N.V. (0001708688) (Filer)
- PRInflaRx Regains Compliance with Nasdaq Minimum Bid Price RequirementJENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company"), today announced that it has received a written notice (the "Notice"), dated April 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with Nasdaq's minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement"). According to the Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the C
- ANALYSTOppenheimer resumed coverage on InflaRx with a new price targetOppenheimer resumed coverage of InflaRx with a rating of Outperform and set a new price target of $5.00 from $7.00 previously
- SECSEC Form 6-K filed by InflaRx N.V.6-K - InflaRx N.V. (0001708688) (Filer)
- SECSEC Form 6-K filed by InflaRx N.V.6-K - InflaRx N.V. (0001708688) (Filer)
- PRInflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR InhibitorJENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions (DDIs) and liver toxicity. These results further support izicopan's potential as a differentiated, best-in-class oral C5a receptor (C5aR) inhibitor. To build upon previous CYP interaction data for izicopan, which showed only marginal inhibition of CYP3A4 (IC₅₀ = 62 µM) in a time-dependent inhibition (TDI) IC₅₀ shift assay, Infla
- SECSEC Form 6-K filed by InflaRx N.V.6-K - InflaRx N.V. (0001708688) (Filer)
- PRInflaRx Announces Participation in the Raymond James 2026 Biotech Innovation SymposiumJENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows: Raymond James 2026 Biotech Innovation SymposiumApril 14, 2026, in New York, NYThe Company will hold one-on-one investor meetings. About InflaRxInflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement
- SECSEC Form 20-F filed by InflaRx N.V.20-F - InflaRx N.V. (0001708688) (Filer)
- SECSEC Form 6-K filed by InflaRx N.V.6-K - InflaRx N.V. (0001708688) (Filer)
- PRInflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected MilestonesPromising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b readiness for izicopan in hidradenitis suppurativa (HS)InflaRx actively reviewing and considering additional development in ANCA‑associated vasculitis (AAV)To broaden izicopan signal-finding activities and expedite proof-of-concept studies into additional indications in inflammation and immunology (I&I), InflaRx intends to conduct a pharmacokinetic (PK) bridging study in China this yearActive dialog with potential collaborators to expedite the Company's total pipeline development goals continuesInflaRx
- INSIDERSEC Form 3 filed by InflaRx N.V.3 - InflaRx N.V. (0001708688) (Issuer)
IFRX FAQ
7 questionsWhat does InflaRx N.V. do?
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated...Where does IFRX stock trade?
InflaRx N.V. (IFRX) is listed on NASDAQ.What sector and industry is IFRX in?
InflaRx N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did InflaRx N.V. go public?
InflaRx N.V. (IFRX) completed its IPO in 2017.What are analysts saying about IFRX?
InflaRx N.V. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $900.00 price target on 2026-05-13. Recent price targets range from $200.00 to $1000.00.What companies are similar to IFRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IFRX side-by-side with any of them on Quantisnow.How can I track IFRX on Quantisnow?
Quantisnow aggregates InflaRx N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IFRX to receive live email and push alerts on every new disclosure.